CVRx Inc (CVRX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, CVRx Inc (CVRX) has a cash flow conversion efficiency ratio of -0.418x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-12.16 Million) by net assets ($29.11 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See net asset quality index of CVRx Inc to measure how much of total assets are equity-financed.
CVRx Inc - Cash Flow Conversion Efficiency Trend (2019–2025)
This chart illustrates how CVRx Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore CVRx Inc debt service capacity to assess how comfortably operating cash covers total debt obligations.
CVRx Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of CVRx Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Mirae Asset Daewoo Co Ltd
KO:006805
|
-0.323x |
|
Luo Lih Fen Holding Co Ltd
TW:6666
|
-0.050x |
|
AURRIGO INT.PLCLS-002
F:CI0
|
N/A |
|
FarmStory Co. Ltd
KQ:027710
|
0.077x |
|
Xin Chio Global Co Ltd
TWO:3171
|
0.084x |
|
Lacroix Group SA
PA:LACR
|
0.145x |
|
Maat Pharma SA
PA:MAAT
|
-1.853x |
|
Pmv Pharmaceuticals Inc
NASDAQ:PMVP
|
-0.189x |
Annual Cash Flow Conversion Efficiency for CVRx Inc (2019–2025)
The table below shows the annual cash flow conversion efficiency of CVRx Inc from 2019 to 2025. For the full company profile with market capitalisation and key ratios, see CVRX market cap.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $39.32 Million | $-40.17 Million | -1.022x | -85.43% |
| 2024-12-31 | $71.06 Million | $-39.14 Million | -0.551x | -7.22% |
| 2023-12-31 | $75.95 Million | $-39.02 Million | -0.514x | -31.44% |
| 2022-12-31 | $109.18 Million | $-42.68 Million | -0.391x | -105.73% |
| 2021-12-31 | $145.96 Million | $-27.73 Million | -0.190x | -446.14% |
| 2020-12-31 | $-293.24 Million | $-16.10 Million | 0.055x | +19.80% |
| 2019-12-31 | $-279.04 Million | $-12.79 Million | 0.046x | -- |
About CVRx Inc
CVRx, Inc., a commercial-stage medical device company, engages in developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases in the United States, Germany, and internationally. The company offers Barostim, an implantable device that delivers electrical pulses to baroreceptors located in the wall of the carotid artery to counteract decreased … Read more